Chandan Nayak

Mr. Chandan Nayak

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
PVPallavi Kishor Vawhal
Pallavi Kishor Vawhal
SJShailaja Bhanudas Jadhav
Shailaja Bhanudas Jadhav
SKSumit Kaushik
Sumit Kaushik
KPKAHNU CHARAN PANIGRAHI
KAHNU CHARAN PANIGRAHI
CNChandan Nayak
Chandan Nayak
IIIbrahim Abdel Aziz Ibrahim
Ibrahim Abdel Aziz Ibrahim
Recent research on dipeptidyl peptidase-IV (DPP-IV) inhibitors has made it feasible to treat type 2 diabetes mellitus (T2DM) with minimal side effects. Therefore, in the present investigation, we aimed to discover and develop some coumarin-based sulphonamides as potential DPP-IV inhibitors in light of the fact that molecular hybridization of many bioactive pharmacophores frequently results in synergistic activity. Each of the proposed derivatives was subjected to an in silico virtual screening, and those that met all of the criteria and had a higher binding affinity with the DPP-IV enzyme were then subjected to wet lab synthesis, followed by an in vitro biological evaluation. The results of the pre-ADME and pre-tox predictions indicated that compounds 6e, 6f, 6h, and 6m to 6q were inferior and violated the most drug-like criteria. It was observed that 6a, 6b, 6c, 6d, 6i, 6j, 6r, 6s, and 6t displayed less binding free energy (PDB ID: 5Y7H) than the reference inhibitor and demonstrated drug-likeness properties, hence being selected for wet lab synthesis and the structures being confirmed by spectral analysis. In the in vitro enzyme assay, the standard drug Sitagliptin had an IC50 of 0.018 µM in the experiment which is the most potent. All the tested compounds also displayed significant inhibition of the DPP-IV enzyme, but 6i and 6j demonstrated 10.98 and 10.14 µM IC50 values, respectively, i.e., the most potent among the synthesized compounds. Based on our findings, we concluded that coumarin-based sulphonamide derivatives have significant DPP-IV binding ability and exhibit optimal enzyme inhibition in an in vitro enzyme assay.

4 December 2025 in Biomedical Materials & Devices
Verified
Journal Article
Closed access
PDF file
CNChandan Nayak
Chandan Nayak
RSRanjit Prasad Swain
Ranjit Prasad Swain
RMRajaram Mohapatra
Rajaram Mohapatra
KPKAHNU CHARAN PANIGRAHI
KAHNU CHARAN PANIGRAHI

30 September 2022 in International journal of health sciences
Verified
Journal Article
Open access
PDF file
RSRanjit Prasad Swain
Ranjit Prasad Swain
NKNihar Ranjan Kar
Nihar Ranjan Kar
BKBodala Chandrika Kumari
Bodala Chandrika Kumari
BPBiswanath Prusty
Biswanath Prusty
JBJochhana Rani Bhuyan
Jochhana Rani Bhuyan
CNChandan Nayak
Chandan Nayak
Diabetes mellitus, which has high rates of disability and mortality, is one of the main causes of public health concerns worldwide. It currently poses serious medical and societal issues. Different bio-analytical techniques have been developed to identify the pharmaceutical formulation of the anti-diabetic drug. Due to the continual requirement to achieve improved sensitivity, accuracy, and speed of analysis in complex biological samples, the development of bio-analytical sample preparation techniques has grown more difficult over time (e.g., blood, serum, plasma, saliva, feces, and urine). This is a mini review, and its goal is to analyze how LC-MS/MS has been used to for the pharmaceutical formulation of the anti-diabetic drugs. The method was validated for linearity, accuracy, precision, specificity, selectivity, and stability.